Role of bromodomain and extraterminal (BET) proteins in prostate cancer

A Mandl, MC Markowski, MA Carducci… - Expert opinion on …, 2023 - Taylor & Francis
Introduction The bromodomain and extraterminal (BET) family of proteins are epigenetic
readers of acetylated histones and are critical activators of oncogenic networks across many …

RB functions as a key regulator of senescence and tumor suppression

M Gao, H Li, J Zhang - Seminars in Cancer Biology, 2024 - Elsevier
The Retinoblastoma (RB) protein is crucial for regulating gene transcription and chromatin
remodeling, impacting cell cycle progression, cellular senescence, and tumorigenesis …

The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma

M Feng, H Xu, W Zhou, Y Pan - Journal of Experimental & Clinical Cancer …, 2023 - Springer
Background Advanced gastric cancer (GC) is a lethal malignancy, harboring recurrent
alterations in cell cycle pathway, especially the CDKN2A-CDK4/CDK6/CCND1 axis …

Co‐targeting BET, CBP, and p300 inhibits neuroendocrine signalling in androgen receptor‐null prostate cancer

N Choo, S Keerthikumar, S Ramm… - The Journal of …, 2024 - Wiley Online Library
There are diverse phenotypes of castration‐resistant prostate cancer, including
neuroendocrine disease, that vary in their sensitivity to drug treatment. The efficacy of BET …

[HTML][HTML] Pyronaridine as a Bromodomain-Containing Protein 4-N-Terminal Bromodomain (BRD4-BD1) Inhibitor: In Silico Database Mining, Molecular Docking, and …

MAA Ibrahim, MMH Abdelhamid, KAA Abdeljawaad… - Molecules, 2023 - mdpi.com
BRD4 (bromodomain-containing protein 4) is an epigenetic reader that realizes histone
proteins and promotes the transcription of genes linked to cancer progression and non …

Gain-of-function mutant p53 together with ERG proto-oncogene drive prostate cancer by beta-catenin activation and pyrimidine synthesis

D Ding, AM Blee, J Zhang, Y Pan, NA Becker… - Nature …, 2023 - nature.com
Whether TMPRSS2-ERG fusion and TP53 gene alteration coordinately promote prostate
cancer (PCa) remains unclear. Here we demonstrate that TMPRSS2-ERG fusion and TP53 …

BRD4 promotes immune escape of glioma cells by upregulating PD-L1 expression

Y Liu, L Cai, H Wang, L Yao, Y Wu, K Zhang… - Journal of Neuro …, 2024 - Springer
Purpose Glioblastoma multiforme (GBM) poses significant challenges in treatment due to its
aggressive nature and immune escape mechanisms. Despite recent advances in immune …

[HTML][HTML] Effective therapeutic targeting of tumor lineage plasticity in neuroendocrine prostate cancer by BRD4 inhibitors

X Zhang, Y Yang, H Zou, Y Yang, X Zheng… - … Pharmaceutica Sinica B, 2025 - Elsevier
Tumor lineage plasticity (LP) is an emerging hallmark of cancer progression. Through
pharmacologically probing the function of epigenetic regulators in prostate cancer cells and …

[HTML][HTML] Unlocking the therapeutic potential of selective CDK7 and BRD4 Inhibition against multiple myeloma cell growth

Y Yao, S Deng, JF Ng, M Yuan, C Chakraborty… - …, 2024 - pmc.ncbi.nlm.nih.gov
Multiple myeloma (MM) is a plasma cell malignancy that is considered incurable despite the
recent therapeutic advances. Effective targeted therapies are, therefore, needed. Our …

Targeted inhibition of BET proteins in HPV-16 associated head and neck squamous cell carcinoma reveals heterogeneous transcription response

A Rao, Z Ni, D Suresh, C Mohanty, AR Wang… - …, 2023 - pmc.ncbi.nlm.nih.gov
Integrated human papillomavirus (HPV-16) associated head and neck squamous cell
carcinoma (HNSCC) tumors have worse survival outcomes compared to episomal HPV-16 …